CMAs are a new class of medicines which harness a natural metabolic process, thus targeting diseases such as obesity.

In November 2022, the USA-based company presented positive top-line results from a Phase IIa trial evaluating the safety and efficacy of its lead product, the small molecule therapy HU6, to address liver fat and total body fat in patients with non-alcoholic fatty liver disease.